A/S, a global healthcare giant specializing in diabetes care and obesity treatment, continues to dominate the GLP-1 drug market alongside competitor Eli Lilly (NYSE:LLY). With a market capitalization ...

Attorney General Keith Ellison announced a settlement with Novo Nordisk that let's Minnesotans buy its insulin products for ...

Minnesota A.G. Keith Ellison says his office settled with Novo Nordisk to cap monthly out-of-pocket payments for insulin at ...

Novo Nordisk (NVO) has reportedly settled a lawsuit filed by the state of Minnesota over the pricing of its insulin products ...

A Novo Nordisk A/S investor says the pharmaceutical company’s failure to disclose how it tested experimental obesity shot ...

Novo Nordisk announced positive trial results for its next-generation obesity drug, leading to a 7.13% surge in its share ...

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

Novo Nordisk and Valo Health have expanded their agreement to discover and develop new treatments for type 2 diabetes, ...

Lexington: Novo Nordisk A/S and Valo Health, Inc. have announced they have entered into an expanded agreement to discover and develop novel treatments for obesity, type 2 diabetes, and cardiovascular ...

Novo Nordisk announced that it is expanding its previous collaboration with Valo Health to discover and develop novel treatments for cardiometabolic diseases. The companies had originally signed ...

Novo Nordisk A/S, a leading global healthcare company, and Valo Health, Inc. announced they have entered into an expanded agreement to discover and develop novel treatments for obesity, type 2 ...